Working… Menu

Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00053794
Recruitment Status : Completed
First Posted : February 6, 2003
Last Update Posted : November 9, 2010
National Cancer Institute (NCI)
Information provided by:
Canadian Cancer Trials Group

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or locally advanced soft tissue sarcoma.

Condition or disease Intervention/treatment Phase
Endometrial Cancer Sarcoma Drug: perifosine Phase 2

Detailed Description:


  • Determine the efficacy of perifosine, in terms of response rate and duration of response, in patients with untreated metastatic or locally advanced soft tissue sarcoma.
  • Determine the toxicity of this drug in these patients.
  • Determine the early progression rate in patients treated with this drug.

OUTLINE: This is a non-randomized, non-blinded, multicenter study.

Patients receive a loading dose of oral perifosine twice on day 1 and then once daily on days 2-21 for the first course. For all subsequent courses, patients receive a loading dose of oral perifosine once on day 1 and then once daily on days 2-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for 1 month. Patients with stable or responsive disease are followed every 3 months thereafter.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma
Study Start Date : May 2003
Actual Study Completion Date : September 2008

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed metastatic or locally advanced soft tissue sarcoma that is incurable by standard therapies, including any of the following types:

    • Uterine sarcomas

      • Mixed mesodermal
      • Leiomyosarcoma
      • Endometrial stromal sarcoma
    • Alveolar soft part sarcoma
    • Angiosarcoma/lymphangiosarcoma
    • Fibrosarcoma
    • Hemangiopericytoma
    • Leiomyosarcoma
    • Liposarcoma
    • Malignant fibrous histiocytoma
    • Neurogenic sarcoma
    • Pleomorphic rhabdomyosarcoma
    • Synovial sarcoma
    • Unclassifiable sarcoma
    • Undifferentiated sarcoma
  • Excluded diseases include the following:

    • Bone sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma)
    • Embryonal rhabdomyosarcoma
    • Carcinosarcoma
    • Kaposi's sarcoma
    • Malignant mesothelioma
    • Neuroblastoma
    • Gastrointestinal stromal tumor
  • At least 1 unidimensionally measurable site of disease (outside the previously irradiated area) defined as:

    • At least 20 mm by x-ray or physical exam
    • At least 10 mm by spiral CT scan
    • At least 20 mm by non-spiral CT scan NOTE: Bone lesions are not considered measurable

NOTE: Patients whose sole site of disease is within a previously irradiated area are allowed if there is evidence of progression or new lesions in the irradiated field

  • No known brain metastases



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks


  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than upper limit of normal (ULN)
  • AST no greater than 2.5 times ULN


  • Creatinine no greater than ULN


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior allergic reactions attributed to compounds of similar chemical or biological composition to perifosine
  • No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
  • No active or ongoing infection
  • No psychiatric illness or social situation that would limit compliance with study requirements
  • No other concurrent uncontrolled illness


Biologic therapy

  • Not specified


  • No prior systemic chemotherapy for metastatic or locally advanced disease
  • At least 6 months since prior adjuvant chemotherapy
  • No other concurrent cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy (except low-dose, non-myelosuppressive radiotherapy)
  • No concurrent radiotherapy to the sole site of measurable disease or for progressively symptomatic disease


  • At least 4 weeks since prior major surgery


  • No other concurrent anticancer therapy or investigational agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00053794

Layout table for location information
Canada, Alberta
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada, T2N 4N2
Canada, British Columbia
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
Margaret and Charles Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada, N6A 4L6
Mount Sinai Hospital - Toronto
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4
Sponsors and Collaborators
NCIC Clinical Trials Group
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Elizabeth A. Eisenhauer, MD Cancer Centre of Southeastern Ontario at Kingston General Hospital

Publications of Results:
Layout table for additonal information Identifier: NCT00053794     History of Changes
Other Study ID Numbers: I155
CDR0000269476 ( Other Identifier: PDQ )
First Posted: February 6, 2003    Key Record Dates
Last Update Posted: November 9, 2010
Last Verified: March 2010
Keywords provided by Canadian Cancer Trials Group:
adult alveolar soft-part sarcoma
adult angiosarcoma
adult fibrosarcoma
adult leiomyosarcoma
adult liposarcoma
adult synovial sarcoma
endometrial stromal sarcoma
uterine leiomyosarcoma
adult malignant hemangiopericytoma
stage III adult soft tissue sarcoma
stage III uterine sarcoma
stage IV uterine sarcoma
recurrent adult soft tissue sarcoma
recurrent uterine sarcoma
adult malignant fibrous histiocytoma
adult neurofibrosarcoma
adult rhabdomyosarcoma
stage IV adult soft tissue sarcoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female